Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin
Primary Purpose
Insulin Resistance, Hypermetabolism, Hyperglycemia
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Metformin
Sugar pill
Sponsored by
About this trial
This is an interventional treatment trial for Insulin Resistance focused on measuring Burn
Eligibility Criteria
Inclusion Criteria:
- Patient age 10-19
- Primary diagnosis of ≥ 20 Total Burn Surface Area Burn (TBSAB )
Exclusion Criteria:
- Decision not to treat due to burn injury severity
- Known history of AIDS, ARC, HIV
- Pregnancy
- Previous diagnosis (pre -burn) of renal failure, liver disease or hepatic dysfunction- Serum Creatinine >1.5mg/dL for males and >1.4mg/dL for females, after fluid resuscitation (Clinical definition of kidney damage)
- Pre-existing type 1 diabetes mellitus
- Pre Existing type 2 diabetes mellitus and receiving treatment
- Allergies to Metformin
- Acute or chronic acidosis (lactic or any other metabolic type) and renal failure
Sites / Locations
- Shriners Hospitals for Children
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
metformin
Sugar pill
Arm Description
Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
sugar pill up to 3 times per day for 12 months
Outcomes
Primary Outcome Measures
Insulin resistance
As measured by OGTT
Secondary Outcome Measures
Protein synthesis
As measured by stable isotope infusion study
Morbidity
As measured by Organ Failure assessments
Full Information
NCT ID
NCT01666665
First Posted
August 6, 2012
Last Updated
November 26, 2019
Sponsor
The University of Texas Medical Branch, Galveston
Collaborators
Shriners Hospitals for Children
1. Study Identification
Unique Protocol Identification Number
NCT01666665
Brief Title
Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin
Official Title
Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Terminated
Why Stopped
At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.
Study Start Date
November 2012 (Actual)
Primary Completion Date
August 2018 (Actual)
Study Completion Date
April 23, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The University of Texas Medical Branch, Galveston
Collaborators
Shriners Hospitals for Children
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Massive pediatric burns are associated with a persistent and sustained hypermetabolic response characterized by elevated levels of circulating catecholamine's, cortisol, and glucagon's, which can cause extreme muscle wasting, immunodeficiency, and delay in wound healing. Insulin and metformin have demonstrated anabolic activity with minimal associated side effects. However, it is unknown whether the beneficial effects arise from tight euglycemic control or direct effect of insulin action. We hypothesize that during acute hospitalization, administration of metformin at a dose titrated to maintain blood glucose between 80-180 mg/dl will accelerate wound healing and recovery in children with severe thermal injury and will have beneficial long-term effects on muscle strength, immune function, and wound healing.
Detailed Description
Metformin treated patients will be compared to control patients. Both groups will receive insulin therapy for blood glucose >180mg/dl. Insulin will be titrated according to hospital sliding scale.
The use of insulin or metformin will benefit burned children by improving muscle protein build-up, speeding wound healing and reversing growth arrest, improving the immune response, and positively affecting long-term rehabilitation.
The results of this study may initiate a change in standard of care as it is found that simply the reduction of blood glucose by metformin, improves patient outcomes as metformin can be administered without the added complication of hypoglycemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance, Hypermetabolism, Hyperglycemia
Keywords
Burn
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
metformin
Arm Type
Active Comparator
Arm Description
Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
Arm Title
Sugar pill
Arm Type
Placebo Comparator
Arm Description
sugar pill up to 3 times per day for 12 months
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
glucophage
Intervention Description
Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
Intervention Type
Drug
Intervention Name(s)
Sugar pill
Other Intervention Name(s)
placebo
Intervention Description
Sugar pill up to 3 times per day for 12 months
Primary Outcome Measure Information:
Title
Insulin resistance
Description
As measured by OGTT
Time Frame
Measure changes between admission and 2 years post burn
Secondary Outcome Measure Information:
Title
Protein synthesis
Description
As measured by stable isotope infusion study
Time Frame
Measure changes between admission and 1 years post burn
Title
Morbidity
Description
As measured by Organ Failure assessments
Time Frame
Measure changes between admission and 2 years post burn
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient age 10-19
Primary diagnosis of ≥ 20 Total Burn Surface Area Burn (TBSAB )
Exclusion Criteria:
Decision not to treat due to burn injury severity
Known history of AIDS, ARC, HIV
Pregnancy
Previous diagnosis (pre -burn) of renal failure, liver disease or hepatic dysfunction- Serum Creatinine >1.5mg/dL for males and >1.4mg/dL for females, after fluid resuscitation (Clinical definition of kidney damage)
Pre-existing type 1 diabetes mellitus
Pre Existing type 2 diabetes mellitus and receiving treatment
Allergies to Metformin
Acute or chronic acidosis (lactic or any other metabolic type) and renal failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David N Herndon, MD
Organizational Affiliation
University of Texas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shriners Hospitals for Children
City
Galveston
State/Province
Texas
ZIP/Postal Code
77551
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin
We'll reach out to this number within 24 hrs